Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium‐Glucose Cotransporter‐2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

(2020) Mark C. Petrie et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Diabetes Minimally Mediated the Association Between PM2.5 Air Pollution and Kidney Outcomes

(2020) Benjamin Bowe et al.   Scientific Reports

Nephroprotection by SGLT2 Inhibition: Back to the Future?

(2020) Luca De Nicola et al.   Journal of Clinical Medicine

Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events

(2020) Yan Xie et al.   DIABETES CARE

Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases

(2020) Yan Xie et al.   DIABETES CARE

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19

(2020) Benjamin Bowe et al.   Clinical Journal of the American Society of Nephrology

Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study

(2020) Yan Xie et al.   BMJ-British Medical Journal

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

(2020) Bettina J. Kraus et al.   KIDNEY INTERNATIONAL

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

(2019) Pantelis Sarafidis et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution

(2019) Benjamin Bowe et al.   BMJ Open

Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study

(2019) Yan Xie et al.   BMJ-British Medical Journal

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging

(2019) Kengo Kidokoro et al.   CIRCULATION

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

(2019) Ofri Mosenzon et al.   Lancet Diabetes & Endocrinology

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

(2019) Erik J.M. van Bommel et al.   KIDNEY INTERNATIONAL

SGLT2 inhibition and kidney protection

(2018) Josselin Nespoux et al.   CLINICAL SCIENCE

Blood urea nitrogen and risk of insulin use among people with diabetes

(2018) Yan Xie et al.   Diabetes & Vascular Disease Research

Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus

(2018) Yan Xie et al.   KIDNEY INTERNATIONAL

Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016

(2018) Yan Xie et al.   KIDNEY INTERNATIONAL

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury

(2017) Yan Xie et al.   KIDNEY INTERNATIONAL

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans

(2017) Yan Xie et al.   BMJ Open

Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD

(2016) Y. Xie et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

(2016) Hiddo J. L. Heerspink et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Inverse odds ratio-weighted estimation for causal mediation analysis

(2013) Eric J. Tchetgen Tchetgen   STATISTICS IN MEDICINE

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

Negative Controls

(2010) Marc Lipsitch et al.   EPIDEMIOLOGY

Constructing Inverse Probability Weights for Marginal Structural Models

(2008) S. R. Cole et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY